Tumor priming to promote nanoparticle gene delivery

肿瘤启动促进纳米颗粒基因传递

• 批准号: 6965749
• 负责人: M GUILLAUME WIENTJES
• 金额: $ 19.29万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-10 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6965749
• 关键词: antineoplastics; bioengineering /biomedical engineering; biotechnology; combination cancer therapy; female; gene delivery system; gene therapy; laboratory mouse; liposomes; nanotechnology; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; paclitaxel; particle; pharmacokinetics; small molecule; therapy design /development; transfection; transfection /expression vector

DESCRIPTION (provided by applicant): Insufficient delivery of gene vectors has been a major limiting factor in gene therapy of cancer. Hence, successful establishment of a technology that promotes gene vector delivery, especially the nonviral vectors that are less likely to elicit significant, potentially fatal host toxicities as have been observed with viral vectors, has the potential of advancing the use of gene therapy. Our laboratory recently demonstrated that the major determinants of penetration of large molecules in solid tumors are tissue structure and composition, and tumor cell density. We further showed that disruption of tumor structure and reduction of tumor cell density can be accomplished by using drugs such as paclitaxel and doxorubicin that induce apoptosis (referred to as tumor priming). This, in turn, results in expanded interstitial space and consequently greater and more even tumor penetration of large molecules (administered after apoptosis has occurred), both in 3-dimensional tumor histocultures and in tumors implanted in animals. We will test the hypothesis that tumor priming enhances nanoparticle delivery, by studying the delivery and spatial distribution of fluorescence-labeled latex beads and liposomes in solid tumors. Our preliminary results indicate that a single paclitaxel treatment improved the delivery of latex beads (100 nm in diameter) to solid tumors. Further, studies are proposed to define the particle characteristics giving the most favorable enhancement of delivery with the tumor priming approach, define the time course of changes in the tumor architecture, and determine the effect of priming in tumor regions with different perfusion characteristics. Studies will focus on liposomes, as these are effective nonviral gene vectors. This data is needed to determine the window of opportunity for delivering gene therapy after tumor priming and to determine the potential utility and limitations of the technology. Successful completion of the proposed studies would provide a new paradigm for delivery of nonviral gene vectors and other nanoparticles, and provide the background information on which we can formulate further studies into the mechanism of particle delivery to tumors.

描述（由申请人提供）：基因载体的不充分递送一直是癌症基因治疗的主要限制因素。因此，成功建立一种促进基因载体递送的技术，特别是不太可能引起显著的、潜在致命的宿主毒性的非病毒载体，如已经用病毒载体观察到的，具有推进基因治疗的使用的潜力。我们的实验室最近证明，实体瘤中大分子渗透的主要决定因素是组织结构和组成以及肿瘤细胞密度。我们进一步表明，肿瘤结构的破坏和肿瘤细胞密度的降低可以通过使用药物如紫杉醇和阿霉素诱导细胞凋亡（称为肿瘤引发）来实现。这反过来又导致扩大的间隙空间，从而导致大分子（在凋亡发生后给药）更大更均匀的肿瘤渗透，无论是在三维肿瘤组织培养物中还是在植入动物体内的肿瘤中。我们将通过研究荧光标记的乳胶珠和脂质体在实体瘤中的递送和空间分布来检验肿瘤引发增强纳米颗粒递送的假设。我们的初步结果表明，单次紫杉醇治疗改善了乳胶珠（直径100 nm）向实体瘤的递送。此外，提出了研究来定义用肿瘤引发方法提供最有利的递送增强的颗粒特性，定义肿瘤结构变化的时间过程，并确定在具有不同灌注特性的肿瘤区域中引发的效果。研究将集中在脂质体，因为它们是有效的非病毒基因载体。需要这些数据来确定肿瘤引发后提供基因治疗的机会窗口，并确定该技术的潜在效用和局限性。这些研究的成功完成将为非病毒基因载体和其他纳米颗粒的递送提供一个新的范例，并为我们进一步研究颗粒递送至肿瘤的机制提供背景信息。